Summary
We studied 24 patients undergoing cardiac surgery or esophagectomy, and necessitating postoperative mechanical ventilation. The initial and maintenance doses of pipecuronium (0.08 mg/kg which is approximately 2 × ED95, and 0.04 mg/kg, respectively) were given during the surgery, and the continuous intravenous infusion of pipecuronium was given in the ICU after surgery. The neuromuscular blockades (NMBs) produced by the relaxant were evaluated with an evoked compound electromyogram. The plasma concentrations of pipecuronium were determined 5 min after the administration of pipecuronium, at 10 % recovery from the complete NMB during surgery and one time a day during the continuous intravenous infusion of the drug in the ICU. The clinical durations of the maintenance dose of pipecuronium in the hypothermic state (core temperature 25.8±0.3° C) during cardiopulmonary bypass (CPB) and in the normothermic states, before and after CPB (core temperature 36.0±0.2°C and 35.7±0.3°C) were 295±18, 107±13 and 143±18 minutes, respectively. The repeated administration of the maintenance dose did not produce prolongation of the clinical duration in the normothermic state of esophagectomy patients. The required infusion rates of pipecuronium were 0.035±0.004 mg/kg/h (0.02–0.06 mg/kg/h) in the ICU. The plasma concentrations of pipecuronium 5 min after the administration of it in cardiac surgery and esophagectomy patients were 508.0±71.3 ng/ml, 524.0±45.0 ng/ml in the initial dose, and 418.3±31.3 ng/ml, 413.7±31.5 ng/ml in the maintenance dose, respectively. The plasma concentrations of pipecuronium for 90% block in hypothermic state of cardiac surgery patients and in normothermic state of esophagectomy patients were 38.8±4.9 ng/ml (23.3–59.8 ng/ml) and 117.0±10.3 ng/ml (50.2–192.1 ng/ml), respectively.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agoston S. The use and misuse of neuromuscular blocking agents in the intensive care unit. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 109–16.
Miller RD. Pharmacokinetics of neuromuscular blocking drugs in intensive care patients. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 117–125.
Coursin DB, Klasek G, Goelzer S. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 1989; 69: 518–521.
Griffin D, Fairman N, Coursin D, Rawsthorne L, Grossman JE. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992; 102: 510–514.
Klessig HT, Geiger RJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologists in the use of muscle relaxants. Crit Care Med 1992; 20: 1441–1445.
Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. JAMA 1992; 266: 2870–2875.
Khuenl-Brady KS, Reitstatter B, Schlager A, Schreithofer D, Luger T, Seyr M, Mutz N, Agoston S. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78: 1082–1086.
Tsuchihashi H, Tatsuno M, Nishikawa M. The analysis of quaternay ammonium compounds by pyrolysis gas chromatography/mass spectrometry and thin-layer chromatography. EISEI KAGAKU 1990; 36: 28–35.
Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. 1987; 67: 1149–1153.
Foldes FF, Kuze S, Vizi ES, Deery A. The influence of temperature on neuromuscular performance. J Neural Transmission 1978; 43: 27–45.
Smith NT, Corbacio AN. Drug interaction in anesthesia. 1986; 2nd Edition: 363–390, Lea & Febiger, Philadelphia.
Miller RD, Savarese JJ. Pharmacology of muscle relaxants, their antagonists, and monitoring of neuromuscular function. Anesthesia 1981; Vol. 1. Edited by Miller RD: 487–538, Churchill Livingstone, New York.
Agoston S, Wierda Swen J. The clinical pharmacology of pipecuronium bromide. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 137–147.
Tassonyi E, Szabo G, Vimlati L. The use of pipecuronium — Arduanr — in anaesthesiology. In: Kharkevich DA, ed. Handbook of experimental pharmacology. 1986; vol. 79. 599–616.
Wierda JMKH, Richardson OM, Agoston S. Dose response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol/fentanyl. Anesth Analg 1989; 69: 208–213.
Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology 1990; 72: 566–570.
Cronnelly R, Fisher DM, Miller RD, Gencarelli P, Nguyen-Gruenke L, Castagnoli Jr N. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized man. Anesthesiology 1983; 58: 405–408.
Segredo V, Matthay MA, Caldwell JE, Sharma ML, Grunke LD, Miller RD. Pharmacodynamics of vecuronium after long-term administration. Anesth Analg 1990; 70: S361.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Japan
About this paper
Cite this paper
Aoki, T. (1995). The Long-Term Use of Pipecuronium in Cardiac and Esophageal Surgery Patients. In: Fukushima, K., Ochiai, R. (eds) Muscle Relaxants. Springer, Tokyo. https://doi.org/10.1007/978-4-431-66896-1_25
Download citation
DOI: https://doi.org/10.1007/978-4-431-66896-1_25
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-66898-5
Online ISBN: 978-4-431-66896-1
eBook Packages: Springer Book Archive